Rami Manochakian: Ponsegromab vs Placebo for treatment of Cachexia in patients with Cancer

Rami Manochakian shared a post on X about a recent paper by John Groarke et al. published in NEJM.

“Ponsegromab for the Treatment of Cancer Cachexia”

Authors: John Groarke, Jeffrey Crawford, Susie Collins, Ruolun Qiu, Aditi Saxena et al.

“Hot off the press.

Just published NEJM in conjunction with presentation ESMO24.

Results of Positive Phase 2 trial of Ponsegromab (GDF15 inhibitor) vs Placebo for treatment of Cachexia in patients with Cancer.”

Ramy Sedhom shared this post, adding:

“A positive trial for cancer cachexia – a very distressing symptom to patients and caregivers! Congrats to my bud Eric Roeland for being an NEJM author.”

Sources: Rami Manochakian/X and Ramy Sedhom/X

More posts featuring Rami Manochakian and Ramy Sedhom on OncoDaily.

Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology.

He is also recognized as a leader in medical education, serving in various educational roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.

Ramy Sedhom holds positions as Assistant Professor of Hematology and Oncology at Perelman School of Medicine and Director of Medical Oncology and Palliative Care at Penn Medicine’s Princeton Medical Center. His work focuses on palliative care integration, geriatric assessment, psycho-oncology, caregiver distress, and remote patient monitoring, with publications in leading journals.

Nationally, he contributes to guideline panels and committees, including the NCCN Guideline Panel for Older Adults with Cancer, and leadership roles within ASCO.